Many Orphan diseases lack treatment owing to their low prevalence in the general population and the Pharma industry’s disinclination to invest in appropriate medications. 

Scientists at Aethrox research orphan diseases and identify pharmaceutical compounds that may prove beneficial in such conditions, when administered via the respiratory route by the company’s unique drug delivery technology.